Published on 12 Jan 2022 on Insider Monkey via Yahoo Finance
We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, smart money investors have to conduct complex analyses, spend many resources and use tools that are not always available for the general crowd. This doesn't mean that they don't have occasional colossal losses; they do (like Melvin Capital's recent GameStop losses). However, it is still a good idea to keep an eye on hedge fund activity. With this in mind, as the current round of 13F filings has just ended, let’s examine the smart money sentiment towards Kymera Therapeutics, Inc. (NASDAQ:KYMR).
Is KYMR a good stock to buy? Hedge fund interest in Kymera Therapeutics, Inc. (NASDAQ:KYMR) shares was flat at the end of last quarter. This is usually a negative indicator. Our calculations also showed that KYMR isn't among the 30 most popular stocks among hedge funds (click for Q2 rankings). At the end of this article we will also compare KYMR to other stocks including Prospect Capital Corporation (NASDAQ:PSEC), Globalstar, Inc. (PINK:GSAT), and Alignment Healthcare, Inc. (NASDAQ:ALHC) to get a better sense of its popularity.
At Insider Monkey, we scour multiple sources to uncover the next great investment idea. For example, lithium prices have more than doubled over the past year, so we go through lists like the 10 best EV stocks to pick the next Tesla that will deliver a 10x return. Even though we recommend positions in only a tiny fraction of the companies we analyze, we check out as many stocks as we can. With all of this in mind we're going to take a gander at the fresh hedge fund action surrounding Kymera Therapeutics, Inc. (NASDAQ:KYMR).